ANIARA

DIAGNOSTICA INC

YOUR LAB DESERVES A PARTNER.
*Not a vendor.*

DOAC REMOVAL · SAMPLE PREPARATION FOR COAGULATION RESEARCH

# Read the plasma — *not the drug.*

Direct oral anticoagulants — **apixaban, rivaroxaban, edoxaban and dabigatran** — interfere with clot-based coagulation assays whenever drug is present in the sample. **DOAC-Remove** adsorbs the drug from a plasma aliquot in vitro, supporting reproducible laboratory research and method-development work on DOAC-containing samples. For Research Use Only.

ACTIVATED-CHARCOAL TABLETS · 5-DIAGNOSTICS

## DOAC-Remove

- Adsorbs **apixaban, rivaroxaban, edoxaban & dabigatran** from a plasma aliquot in vitro.
- Supports **clot-based coagulation research and method development** on DOAC-containing plasma, from a single sample.
- Add one tablet, mix **~10 min**, centrifuge — recover the drug-depleted supernatant for downstream research assays.
- Three sizes: **20 / 50 / 250** preparations (A5D-82410A / B / C).

**A5D-82410A / B / C**

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

$80–556

## DOAC INTERFERENCE REPORTED ACROSS CLOT-BASED ASSAYS

- Lupus anticoagulant (dRVVT)
- APTT-based LA
- Silica clotting time (SCT)
- Protein C / Protein S
- Antithrombin
- APC resistance
- Thrombin time

*Assay names denote scientific context in which DOAC interference is reported in the literature — not clinical-use claims for DOAC-Remove.*

**Why remove the drug in vitro.** DOACs interfere with clot-based coagulation assays, and this interference is well documented in the coagulation literature. Depleting the drug from a plasma aliquot before analysis is a described sample-preparation approach for laboratory research on specimens that contain anticoagulant. DOAC-Remove is intended for that research use only.

**SELECTED REFERENCES** Favaloro EJ. Lupus anticoagulant testing during anticoagulation, including DOACs — *Res. Pract. Thromb. Haemost.* 2022;6(2):e12676. · Frans G, et al. Resolving DOAC interference on aPTT, PT and lupus anticoagulant testing using activated carbon — *J. Thromb. Haemost.* 2019;17:1354. · DOAC-Stop vs DOAC-Remove before thrombophilia/lupus testing — *Br. J. Biomed. Sci.* 2024;81:13359.

**Regulatory: DOAC-Remove** is **For Research Use Only. Not for use in diagnostic procedures.** It is intended for laboratory research and method-development use in removing direct oral anticoagulants from plasma samples. It has not been cleared or approved by the U.S. FDA, nor licensed by Health Canada, for any diagnostic use, and must not be used to generate results for clinical diagnosis or patient management. Removal performance depends on DOAC type and concentration; follow the use protocol supplied with each lot. Assay names denote scientific context in which DOAC interference is reported and are not claims of clinical utility. Pricing shown is US list and subject to change. Therapeutic agents named are referenced as analytes / scientific context and are not Aniara products. © 2026 Aniara Diagnostica, Inc.

Aniara Diagnostica, Inc.
WEST CHESTER, OHIO · 1-866-783-3797

aniara.com
SEARCH "DOAC-REMOVE" · OR ASK YOUR ANIARA REP

5-Diagnostics · DOAC Removal · 5D-011-00 · June 2026